Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Director Sells $1,572,104.21 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $70.13, for a total value of $1,572,104.21. Following the transaction, the director directly owned 51,326 shares of the company’s stock, valued at approximately $3,599,492.38. This represents a 30.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Friday, June 12th, Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock. The stock was sold at an average price of $70.11, for a total value of $882,194.13.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $69.89 on Monday. The stock has a fifty day moving average price of $63.40 and a 200 day moving average price of $44.04. The stock has a market cap of $4.22 billion, a PE ratio of -36.03 and a beta of -0.25. Oruka Therapeutics, Inc. has a 1 year low of $10.77 and a 1 year high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities research analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ORKA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Stifel Nicolaus raised their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research report on Wednesday, June 3rd. Finally, BTIG Research reissued a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 14th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ORKA. Viking Global Investors LP purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $51,280,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $51,840,000. Remedium Capital Partners LLC purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at $47,054,000. Avoro Capital Advisors LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter valued at $25,640,000. Finally, Deep Track Capital LP grew its position in shares of Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after purchasing an additional 735,983 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.